



Christoph A Fux

Kontakt

Christoph A Fux

Publikationen (18)

Roth J, Bogojeska J, Bernasconi E, Kahlert C, Cavassini M, Calmy A, Scherrer A, Fux C, Kouyos R, Günthard H, Rauch A, Marzolini C, Radevski G, Battegay M. Cohort-derived machine learning models for individual prediction of chronic kidney disease in people living with HIV: a prospective multicentre cohort study. *J Infect Dis* 2020

Surial B, Wandeler G, Rauch A, Furrer H, Fux C, Schmid P, Bernasconi E, Stöckle M, Kovari H, Günthard H, Cavassini M, Calmy A, Ledergerber B, Swiss HIV Cohort Study. Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study. *J Infect Dis* 2020

Ruffieux Y, Egger M, Keiser O, Vernazza P, Scherrer A, Marzolini C, Günthard H, Fux C, Cavassini M, Calmy A, Aebi-Popp K, Lemsalu L, Swiss HIV Cohort Study and the Swiss National Cohort. Mortality from suicide among people living with HIV and the general Swiss population: 1988–2017. *J Int AIDS Soc* 2019; 22:e25339.

Bayard C, Hasse B, Tarr P, Fux C, Di Benedetto C, Staehelin C, Weber R, Hoffmann M, Moulin E, Lecompte T, Flepp M, Ledergerber B, Swiss HIV Cohort Study. Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. *Open Forum Infect Dis* 2017; 4:ofx177.

Gueler A, Egger M, Zwahlen M, Vernazza P, Cavassini M, Battegay M, Fux C, Furrer H, Bernasconi E, Günthard H, Calmy A, Moser A. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. *AIDS* 2016

Conen A, Battegay M, Bucher H, Weber R, Vernazza P, Bernasconi E, Calmy A, Orasch C, Thurnheer M, Fux C, Glass T, Wang Q, Fehr J. Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study. *J Acquir Immune Defic Syndr* 2013; 64:472–8.

Drozov D, Buchkremer F, Litke A, Schuetz P, Huber A, Bürgi U, Fux C, Bock A, Müller B, Albrich W, Ottiger C, Reutlinger B, Thomer A, Meili M, Schwarz S, Kouegbe R, Regez K, Guglielmetti M, Schild U, Conca A, Schäfer P, Triple P study group. Procalcitonin, pyuria and proadrenomedullin in the management of urinary tract infections--'triple p in uti': study protocol for a randomized controlled trial. *Trials* 2013; 14:84.

Du Pasquier R, Vernazza P, Cavassini M, Günthard H, Cusini A, Gutmann C, Fux C, Yerly S, Kalubi M, Jilek S, Swiss HIV Cohort Study. Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monootherapy. *AIDS* 2013; 27:203–10.

Cusini A, Günthard H, Opravil M, Gutmann C, Zenger F, Klimkait T, Cavassini M, Gaudenz R, Hirschel B, Widmer N, Rohrbach J, Fux C, Ledergerber B, Decosterd L, Yerly S, Vernazza P, Swiss HIV Cohort Study. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. *J Acquir Immune Defic Syndr* 2013; 62:28–35.

Young J, Bucher H, Battegay M, Weber R, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Furrer H, Fux C, Schäfer J, the Swiss HIV Cohort Study. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. *AIDS* 2012; 26:567–575.

Fehr J, Hirschel B, Vernazza P, Martinetti G, Bernasconi E, Günthard H, Battegay M, Bucher H, Klimkait T, Fux C, Cavassini M, Glass T, Louvel S, Hamy F, Hirsch H, von Wyl V, Böni J, Yerly S, Bürgisser P, Hiv Cohort Study A. Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study. *J Transl Med* 2011; 9:14.

Khanna N, Hirsch H, Battegay M, Bernasconi E, Vernazza P, Fux C, Cavassini M, Garzoni C, Mueller N, Elzi L, Swiss HIV Cohort Study. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2009; 48:1459-66.

Khanna N, Hirsch H, Battegay M, Viscidi R, Bernasconi E, Vernazza P, Fux C, Du Pasquier R, Garzoni C, Mueller N, Wolbers M, Swiss HIV Cohort Study. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. *Journal of virology* 2009; 83:4404-11.

Elzi L, Battegay M, Bernasconi E, Vernazza P, Hirschel B, Cavassini M, Fux C, Weber R, Kaufmann G, Swiss HIV Cohort Study. Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. *HIV clinical trials* 2009; 10:207-14.

Young J, Battegay M, Bernasconi E, Vernazza P, Cavassini M, Hirschel B, Fux C, Rickenbach M, Guenthard H, Bucher H, Swiss HIV Cohort Study. Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. *Antiviral therapy* 2009; 14:771-9.

Fux C, Furrer H, Elzi L, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Hirschel B, Bucher H, Simcock M, Rauch A, Swiss HIV Cohort Study. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. *Antiviral therapy* 2008; 13:1077-82.

Fux C, Furrer H, Elzi L, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Hirschel B, Bucher H, Wolbers M, Simcock M, Swiss HIV Cohort Study. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. *Antiviral therapy* 2007; 12:1165-73.

Wunder D, Furrer H, Mueller B, Bernasconi E, Schmid P, Elzi L, Cavassini M, Hirschel B, Mueller N, Fux C, Bersinger N, Swiss HIV Cohort Study. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. *Antiviral therapy* 2007; 12:261-5.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch